Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
Clin Exp Nephrol
; 28(7): 674-682, 2024 Jul.
Article
em En
| MEDLINE
| ID: mdl-38457030
ABSTRACT
BACKGROUND:
Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.METHODS:
Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.RESULTS:
Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1ß, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.CONCLUSIONS:
HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diálise Renal
/
Imunização Secundária
/
Imunidade Humoral
/
COVID-19
/
Vacina BNT162
/
Anticorpos Antivirais
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article